Drug intelligence / Profile preview

GSK615915A

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Inhalation

Overview

GSK615915A is a novel surfactant developed by GSK for use in the formulation of next-generation Metered Dose Inhalers (MDIs). It is designed to stabilize drug suspensions within the inhaler, ensuring that a consistent and accurate dose of the active medication is delivered with each puff. By improving the physical stability of the formulation, GSK615915A aims to enhance the reliability of inhaled therapies for respiratory conditions. It has been studied in Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in both healthy volunteers and individuals with asthma.

Beyond the preview

Go deeper on GSK615915A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK615915A.

Explore the full profile